Comments on the "Prognostic Impact and Clinicopathological Correlation of CD133 and ALDH1 Expression in Invasive Breast Cancer".

Abstract

To the Editor, We read the paper by Kim et al. [1] concerning the potential predictive role of Prominin 1 (CD133) and aldehyde dehydrogenase 1 (ALDH1) expression in invasive breast cancer, which appeared in the latest issue of this Journal, with great interest. CD133 and ALDH1 have been considered as mark-ers of cancer stem cells, with documented activities in liver, colorectal, prostate, brain, pancreatic, gastric, and breast cancers [2,3,4,5,6]. The precise biological function of CD133 in breast cancer is still controversial since it has been hypothesized that this marker might be involved in different neoplastic processes, such as initiation, cellular migration, and circulation [1,7]. In our opinion, the paper by Kim et al. [1] raises some interesting and relevant points that we have already addressed in our previous papers [8,9]. While some methodological aspects were identical, including the procedure used for antigen retrieval, overnight incubation at 4℃ with the primary antibody, the use of polyclonal rabbit anti-CD133 antibody, and the substrate-chromogen system (3,3'-diaminobenzidine tetrahydrochloride), the immunohistochemical assessment used for obtaining the CD133 score of immunopositivity was different. Kim et al. [1] defined negative staining in all cells with a score of 0; weakly positive or focally positive staining in 50% of the cells, with a score of 3+. On the contrary, we used a scoring method [8,9] that required the quantification of immunostained aggregates (2–5 cells) at three different areas; a score of 1 or 2 was assigned to cases with 33.2% in patients with node-negative breast cancer [8,9]. Therefore, reported differences in the rate of immunopositivity should be attributed either to different scoring methodo-logies, or to surgical samples of different origin. In the study of Kim et al. [1], CD133 expression appeared to be significantly associated with some adverse parameters, such as tumor dimension, nodal metastasis, stage, estrogen receptor/progesterone receptor negativity, human epidermal growth factor receptor 2 (HER2) positivity, and recurrence. In our series [8,9], no significant relationships were noted between CD133 immunopositivity and histotype, tumor grade, stage, and hormone receptor expression, while a significant correlation between CD133 and bone metastasis, Ki-67 score, and HER2 status was identified. However, previous studies showed that CD133 expression was associated with worse clinical behavior in colorectal cancer, although not associated with clinicopathological features [10,11,12]. In conclusion, Kim et al. [1] suggested that CD133 expression, alone or in combination with ALDH1, was widely associated with the presence of adverse biomarkers and subtypes of breast cancer, and could be used in identifying biologically aggressive cases, and in predicting survival outcomes. Similarly, we have revealed interesting relationships between CD133 and predictive parameters (Ki-67 and HER2 status) of poor prognosis in breast cancer, allowing the identification of CD133 immunopositive cases in pN0 breast cancer, characterized by worse clinical behavior. Therefore, we fully agree with the suggestion of Kim et al. [1] that the predictive role of CD133 should be emphasized and, consequently, it should be extensively utilized in the management of patients with breast cancer.